Developing superior Sirolimus drug-coated balloons (DCB)

Advanced NanoTherapies, Inc. is a privately held medical device company committed to using nanotechnology for enhanced drug uptake and sustained retention in the cell for medical devices. We are primarily focused on cardiovascular and endovascular applications and dedicated to bringing a safer therapeutic option to peripheral artery disease (PAD) patients using Sirolimus-coated angioplasty balloons.

“Being part of a startup company has always been in my blood. I see myself as an architect—putting the right technology together with the right team, along with the clinical side of it—the right combination to make it valuable from a commercial standpoint as well as a clinical standpoint.”

Marwan Berrada-Sounni, CEO

Timeline

2018

Advanced NanoTherapies incorporated as a Delaware C-Corp

2019

Licensed technology from Cleveland Clinic (September)

2020

Operation started in January Closed on $5.3M Financing

Timeline

2018

Advanced NanoTherapies incorporated as a Delaware C-Corp

2019

Licensed technology from Cleveland Clinic (September)

2020

Operation started in January Closed on $5.3M Financing

2021 Goals

OUS First-in-Man
US EFS IDE

Leadership Team

CEO: Marwan Berrada-Sounni, MSc, MBA

A successful entrepreneur with extensive experience in cardiovascular and endovascular devices.

CMO: Mehdi Shishehbor, DO, MPH, PhD

Chief Medical Officer and President, Harrington Heart and Vascular Institute University Hospitals, Cleveland

Vinod Labhasetwar, PhD

Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research

Board of Directors

Co-Founder, CEO, and Chairman

Philippe Urbain

Co-Founder and President

Mehdi Shishehbor

Independent Director

Independent Director

Independent Director